Literature DB >> 10860846

The repressive function of AP2 transcription factor on the hepatocyte growth factor gene promoter.

J G Jiang1, M C DeFrances, J Machen, C Johnson, R Zarnegar.   

Abstract

Hepatocyte growth factor is an important multifunctional growth factor whose gene expression is tightly regulated at the transcriptional level. Previous studies from our laboratory have shown that several cis-acting elements are present in the promoter and proximal promoter region of the HGF gene. In this study, we have uncovered that AP2 transcription factor specifically binds to a regulatory site located at -230 to -260 in the upstream region of the HGF gene promoter. Gelshift and supershift assays confirmed that AP2 has high binding affinity to this region. Functional studies which introduced a mutation in the AP2 core binding region as well as cotransfection experiments using an AP2 expression vector revealed that AP2 exerts a repressive role on the HGF gene promoter activity. The AP2 binding site overlaps with those of NF1 and USF/E-box binding sites which we have recently shown to constitute a composite multifunctional docking site for the members of the NF1 and USF transcription factor families. An inverse correlation was noted between AP2 binding activity to this composite site and HGF gene expression in different cell lines. Therefore, AP2-mediated repression of the HGF gene promoter may be part of the molecular mechanism responsible for regulating HGF expression. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10860846     DOI: 10.1006/bbrc.2000.2848

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Activator protein 2 alpha (AP2alpha) suppresses 42 kDa C/CAAT enhancer binding protein alpha (p42(C/EBPalpha)) in head and neck squamous cell carcinoma.

Authors:  Kristi L Bennett; Todd Romigh; Khelifa Arab; Rosemary E Teresi; Yasuhiro Tada; Charis Eng; Christoph Plass
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

2.  Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.

Authors:  Xian-Zhang Hu; Robert H Lipsky; Guanshan Zhu; Longina A Akhtar; Julie Taubman; Benjamin D Greenberg; Ke Xu; Paul D Arnold; Margaret A Richter; James L Kennedy; Dennis L Murphy; David Goldman
Journal:  Am J Hum Genet       Date:  2006-03-28       Impact factor: 11.025

3.  PKC-dependent stimulation of the human MCT1 promoter involves transcription factor AP2.

Authors:  Seema Saksena; Alka Dwivedi; Ravinder K Gill; Amika Singla; Waddah A Alrefai; Jaleh Malakooti; Krishnamurthy Ramaswamy; Pradeep K Dudeja
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-11-25       Impact factor: 4.052

4.  Association of serotonin transporter gene polymorphisms with obsessive-compulsive disorder (OCD) in a south Indian population.

Authors:  Prashant Tibrewal; H B Kiran Kumar; G N Shubha; D Subhashree; Meera Purushottam; K Thennarasu; Y C J Reddy; Sanjeev Jain
Journal:  Indian J Med Res       Date:  2010-12       Impact factor: 2.375

Review 5.  Transcriptional Silencers: Driving Gene Expression with the Brakes On.

Authors:  Julian A Segert; Stephen S Gisselbrecht; Martha L Bulyk
Journal:  Trends Genet       Date:  2021-03-09       Impact factor: 11.821

6.  Maintenance of Chronic Fatigue Syndrome (CFS) in Young CFS Patients Is Associated with the 5-HTTLPR and SNP rs25531 A > G Genotype.

Authors:  Benedicte Meyer; Chinh Bkrong Thuy Nguyen; Aurora Moen; Even Fagermoen; Dag Sulheim; Hilde Nilsen; Vegard Bruun Wyller; Johannes Gjerstad
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

Review 7.  Hepatocyte Growth Factor Isoforms in Tissue Repair, Cancer, and Fibrotic Remodeling.

Authors:  Ognoon Mungunsukh; Elizabeth A McCart; Regina M Day
Journal:  Biomedicines       Date:  2014-11-05

8.  Systematic identification of silencers in human cells.

Authors:  Baoxu Pang; Michael P Snyder
Journal:  Nat Genet       Date:  2020-02-24       Impact factor: 38.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.